1-5 of 5
Robert M. Campbell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in Cancer

Available to Purchase
Robinson Triboulet, Khikmet Sadykov, Darren M. Harvey, David M. Wilson, Michael J. Steinbaugh, Christopher B. Mayo, Dillon Hawley, Andrew Madanjian, Corey Fyfe, Christina Bracken, Izarys Rivera-Rivera, Anna Ericsson, Andrew R. Snyder, Sarah K. Knutson, Ross L. Stein, Veronica Gibaja, Shomir Ghosh, Robert M. Campbell
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (12): 1779–1788.
https://doi.org/10.1158/1535-7163.MCT-24-0176
Published: 03 December 2024
View articletitled, Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in Cancer
Open the PDF for Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in Cancer in another window
Includes: Supplementary data
Journal Articles

Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Free
Jian Du, Lei Yan, Raquel Torres, Xueqian Gong, Huimin Bian, Carlos Marugán, Karsten Boehnke, Carmen Baquero, Yu-Hua Hui, Sonya C. Chapman, Yanzhu Yang, Yi Zeng, Sarah M. Bogner, Robert T. Foreman, Andrew Capen, Gregory P. Donoho, Robert D. Van Horn, Darlene S. Barnard, Jack A. Dempsey, Richard P. Beckmann, Mark S. Marshall, Li-Chun Chio, Yuewei Qian, Yue W. Webster, Amit Aggarwal, Shaoyou Chu, Shobha Bhattachar, Louis F. Stancato, Michele S. Dowless, Phillip W. Iversen, Jason R. Manro, Jennie L. Walgren, Bartley W. Halstead, Matthew Z. Dieter, Ricardo Martinez, Shripad V. Bhagwat, Emiko L. Kreklau, Maria Jose Lallena, Xiang S. Ye, Bharvin K.R. Patel, Christoph Reinhard, Gregory D. Plowman, David A. Barda, James R. Henry, Sean G. Buchanan, Robert M. Campbell
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12): 2207–2219.
https://doi.org/10.1158/1535-7163.MCT-18-0529
Published: 02 December 2019
View articletitled, Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy
Open the PDF for Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy in another window
Includes: Supplementary data
Journal Articles

Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity

Free
Robert M. Campbell, Bryan D. Anderson, Nathan A. Brooks, Harold B. Brooks, Edward M. Chan, Alfonso De Dios, Raymond Gilmour, Jeremy R. Graff, Enrique Jambrina, Mary Mader, Denis McCann, Songqing Na, Stephen H. Parsons, Susan E. Pratt, Chuan Shih, Louis F. Stancato, James J. Starling, Courtney Tate, Juan A. Velasco, Yong Wang, Xiang S. Ye
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (2): 364–374.
https://doi.org/10.1158/1535-7163.MCT-13-0513
Published: 09 February 2014
View articletitled, Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Open the PDF for Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity in another window
Includes: Supplementary data
Journal Articles

Abstract B235: Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity.

Free
Robert M. Campbell, Bryan D. Anderson, Edward M. Chan, Alfonso De Dios, Raymond Gilmour, Steven D. Hatch, Enrique Jambrina, Paul Lee, Mary Mader, Songqing Na, Blake L. Neubauer, Susan Pratt, Chuan Shih, Louis F. Stancato, James J. Starling, Juan A. Velasco, Scott A. Watkins, Jeffrey A. Wolos, Xiang Ye
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B235.
https://doi.org/10.1158/1535-7163.TARG-11-B235
Published: 12 November 2011
View articletitled, Abstract B235: Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity.
Journal Articles

The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines

Free
Chafiq Hamdouchi, Heather Keyser, Elizabeth Collins, Carlos Jaramillo, Jose Eugenio De Diego, Charles D. Spencer, Jack Alan Dempsey, Bryan D. Anderson, Tillie Leggett, Nancy B. Stamm, Richard M. Schultz, Scott A. Watkins, Kim Cocke, Stephanie Lemke, Teresa F. Burke, Richard P. Beckmann, Jeffrey T. Dixon, Thomas M. Gurganus, Nancy B. Rankl, Keith A. Houck, Faming Zhang, Michal Vieth, Juan Espinosa, David E. Timm, Robert M. Campbell, Bharvin K. R. Patel, Harold B. Brooks
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2004) 3 (1): 1–9.
https://doi.org/10.1158/1535-7163.1.3.1
Published: 28 January 2004
View articletitled, The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines
Open the PDF for The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines in another window